Cary Street Partners Financial LLC Invests $15.70 Million in Zoetis Inc. (NYSE:ZTS)

Cary Street Partners Financial LLC acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 96,327 shares of the company's stock, valued at approximately $15,695,000.

Other hedge funds also recently bought and sold shares of the company. Callahan Advisors LLC increased its holdings in Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock worth $2,135,000 after purchasing an additional 6,221 shares during the period. CIBC Asset Management Inc lifted its stake in Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock worth $38,617,000 after acquiring an additional 46,050 shares during the period. Pensionfund Sabic grew its holdings in Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock worth $1,825,000 after acquiring an additional 4,000 shares in the last quarter. Schroder Investment Management Group raised its holdings in shares of Zoetis by 2.6% in the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock valued at $40,036,000 after purchasing an additional 6,169 shares in the last quarter. Finally, PFW Advisors LLC purchased a new stake in shares of Zoetis in the 4th quarter worth approximately $1,764,000. Institutional investors own 92.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ZTS. Stifel Nicolaus cut their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Finally, UBS Group decreased their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Zoetis has an average rating of "Buy" and a consensus target price of $213.56.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. This trade represents a 2.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is owned by corporate insiders.

Zoetis Price Performance

Shares of ZTS stock traded up $6.28 during trading hours on Wednesday, hitting $156.15. 4,453,847 shares of the company's stock were exchanged, compared to its average volume of 2,479,023. The firm has a 50 day moving average of $157.64 and a two-hundred day moving average of $166.61. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The firm has a market cap of $69.67 billion, a P/E ratio of 28.55, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. During the same period last year, the firm posted $1.38 earnings per share. The company's revenue was up 1.4% compared to the same quarter last year. Sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio is presently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.